Semaglutide

About

Semaglutide is a synthetic analog of the endogenous incretin glucagon-like peptide-1 (GLP-1), belonging to the GLP-1 receptor agonist class. It is the only drug in its category with FDA approval in both oral and injectable forms. Research has explored its hypoglycemic effects, its role as an appetite suppressant and weight-management agent, and its association with reduced cardiovascular risk in type 2 diabetes. It is engineered to resist degradation by the dipeptidyl peptidase-IV (DPP-4) enzyme, extending its activity.

Research Applications

• Anti-obesity and weight loss
• Glycemic control
• Cardiovascular health
• Neuroprotection

Mechanism of Action

Semaglutide mimics GLP-1 to stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner, lowering fasting and postprandial blood glucose, while resisting DPP-4 degradation for a longer duration of action.

Molecular Info

Class

Peptide

Length

Synthetic GLP-1 analog (31-amino-acid polypeptide)

Formulations

Subcutaneous injection and oral tablet

Primary research areas

Glycemic control, weight management, cardiovascular health, and neuroprotection

Dosing Guidance

Range

Clinical references describe distinct subcutaneous and oral regimens that vary by indication, with gradual escalation common in clinical use.

Frequency

Once weekly for subcutaneous formulations and daily for the oral tablet, per clinical references.

Timing

Timing is not consistently defined across the available research references.

Cycle length

Cycle length is not consistently defined across the available research references.

Notes

These details are educational context only. Protocol values are examples and should not be treated as medical instructions.

Known Risks

• Gastrointestinal upset and related reactions
• Thyroid C-cell tumors observed in rodent studies
• Contraindicated in Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Reports of acute and chronic pancreatitis

Regulatory & Evidence Status

Evidence level

Extensive clinical trial evidence within approved indications; other uses are investigational.

FDA status

Approved — type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Availability

Prescription medication.